1. Inicio
  2. Proyectos y Estudios
  3. ESTUDIO OBSERVACIONAL, NO INTERVENCIONISTA, PARA EVALUAR LOS CAMBIOS EN LA CALIDAD DE VIDA EN PACIENTES TRATADOS CON TERIFLUNOMIDA EN PRÁCTICA CLÍNICA HABITUAL.

ESTUDIO OBSERVACIONAL, NO INTERVENCIONISTA, PARA EVALUAR LOS CAMBIOS EN LA CALIDAD DE VIDA EN PACIENTES TRATADOS CON TERIFLUNOMIDA EN PRÁCTICA CLÍNICA HABITUAL.

Datos básicos

Código:
SAN-TER-2015-02
Protocolo:
SAN-TER-2015-02
EUDRACT:
NCT:
Centro:
HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
Dotación:
Año de incio:
2016
Año de finalización:
2019
ESTUDIO OBSERVACIONAL NACIONAL

Documentos

  • No hay documentos

Participantes

Grupos

Financiadores - Promotores

SANOFI AVENTIS S.A

Resultados del Ensayo Clínico

An algorithm to predict intrathecal synthesis of IgG with high efficiency

Tortosa-Carreres, Jordi; (...); Casanova, Bonaventura

Meeting Abstract. 2023


An expanded parenchymal CD8+ T cell clone in GABA A receptor encephalitis.

Bracher A; (...); Dornmair K

Article. 10.1002/acn3.50974. 2020


Anti-CD20 monoclonal antibodies in primary progressive multiple sclerosis: a real-life comparative study of rituximab vs. ocrelizumab

Alcala, C.; (...); Casanova, B.

Meeting Abstract. 2021


Assessment of Plasma and Cerebrospinal Fluid Biomarkers in Different Stages of Alzheimer's Disease and Frontotemporal Dementia.

Álvarez-Sánchez L; (...); Cháfer-Pericás C

Article. 10.3390/ijms24021226. 2023


Association of Complement Factors With Disability Progression in Primary Progressive Multiple Sclerosis.

Lunemann JD; (...); Comabella M

Article. 10.1212/NXI.0000000000200270. 2024


Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs.

Monreal, Enric; (...); Villar LM

Article. 10.1001/jamaneurol.2023.0010. 2023


Atypical periodic alternating nystagmus responding to high-dose intravenous immunoglobulins: a case report

Argente-Escrig, H; (...); Casanova Estruch B

Article. 10.1186/s12974-017-0846-1. 2017


Autologous hematopoietic stem cell transplantation for pediatric multiple sclerosis: a registry-based study of the Autoimmune Diseases Working Party (ADWP) and Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Burman, J; (...); Farge, D

Article. 10.1038/bmt.2017.40. 2017


Autologous hematopoietic stem cell transplantation in multiple sclerosis: updating outcomes in the Valencian cohort.

Boix Lago, A.; (...); Casanova Estruch, B.

Meeting Abstract. 2023


Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis

Casanova, B; (...); Coret, F

Article. 10.1007/s10072-017-2933-6. 2017


Basal levels of serum neurofilament light in normal aging and multiple sclerosis patients

Gasque Rubio, R.; (...); Casanova Estruch, B.

Meeting Abstract. 2021


Bioenergetic Failure in Rat Oligodendrocyte Progenitor Cells Treated with Cerebrospinal Fluid Derived from Multiple Sclerosis Patients

Mathur, D; (...); Lopez-Rodas, G

Article. 10.3389/fncel.2017.00209. 2017


Brain atrophy in relapsing optic neuritis is associated to anti-mog antibodies

Navarro Canto, L.; (...); Casanova Estruch, B.

Meeting Abstract. 2019


Brain Atrophy in Relapsing Optic Neuritis Is Associated With Crion Phenotype

Canto, LN; (...); Estruch, BC

Article. 10.3389/fneur.2019.01157. 2019


Brain region volumes and their relationship with disability progression and cognitive function in primary progressive multiple sclerosis.

Perez-Miralles, Francisco Carlos; (...); Casanova, Bonaventura

Article. 10.1002/brb3.2044. 2021


Case Report: Exacerbation of Relapses Following mRNA COVID-19 Vaccination in Multiple Sclerosis: A Case Series.

Quintanilla-Bordás C; (...); Casanova B

Article. 10.3389/fneur.2022.897275. 2022


Cerebrospinal fluid kappa free light chains and IgM index for diagnosis and prognosis in multiple sclerosis

Gil-Perotin, S.; (...); Casanova, B.

Meeting Abstract. 2021


Cervical spinal cord T2 lesions independently predict early conversion to secondary progressive multiple sclerosis: a longitudinal 10-year study

Lacruz-Ballester, L.; (...); Casanova-Estruch, B.

Meeting Abstract. 2021


Circulating mirna signatures in PPMS

Martin, MMS; (...); Torrenta, LRI

Meeting Abstract. 2020


Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: DISCOVER study

Oreja-Guevara, Celia; (...); Rio, Jordi

Article. 10.1016/j.msard.2024.105787. 2024


Clinical trajectories of patients with multiple sclerosis from onset and their relationship with serum neurofilament light chain levels

Quintanilla-Bordas, Carlos; (...); Casanova, Bonaventura

Article. 10.3389/fneur.2024.1477335. 2024


Clinical, demographic and laboratory data associated with PML risk in patients treated with natalizumab

Toboso, I; (...); Villar, LM

Meeting Abstract. 2017


Cognitive impairment in multiple sclerosis: diagnosis and monitoring.

Meca-Lallana, Virginia; (...); Perez-Miralles, Francisco

Article. 10.1007/s10072-021-05165-7. 2021


Cognitive performance and health-related quality of life in patients with neuromyelitis optica spectrum disorder

Lopez-Soley, Elisabet; (...); Solana, Elisabeth

Meeting Abstract. 2022

  • Open Access.

Cognitive Performance and Health-Related Quality of Life in Patients with Neuromyelitis Optica Spectrum Disorder.

Lopez-Soley E; (...); Solana E

Article. 10.3390/jpm12050743. 2022


Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis.

Gil-Perotin S; (...); Casanova B

Article. 10.3389/fneur.2019.01008. 2019


Comparative Assessment of Simoa and Lumipulse for Measuring Serum Neurofilament Light Chain in Multiple Sclerosis Patients

Gasque-Rubio, Raquel; (...); Perez-Miralles, Francisco

Article. 10.1155/2024/1950913. 2024


Consensus document on the multidisciplinary management of neurogenic lower urinary tract dysfunction in patients with multiple sclerosis.

Medina-Polo J; (...); López-Fando L

Article. 10.1002/nau.24276. 2020


Consensus guidelines for the timely detection and diagnosis of disease progression in multiple sclerosis patients

Oreja-Guevara, C; (...); Meca-Lallana, J

Meeting Abstract. 2020


Consensus on early detection of disease progression in patients with multiple sclerosis

Meca-Lallana, Jose E.; (...); Oreja-Guevara, Celia

Article. 10.3389/fneur.2022.931014. 2022


Cross-reactivity of a pathogenic autoantibody to a tumor antigen in GABA A receptor encephalitis.

Brändle SM; (...); Dornmair K

Article. 10.1073/pnas.1916337118. 2021


CSF chitinase 3-like-1 association with disability of primary progressive MS

Perez-Miralles, F; (...); Casanova, B

Article. 10.1212/NXI.0000000000000815. 2020


Changes in Brain Volume in Specific Regions could be related to Disability Progression in Primary Progressive Multiple Sclerosis Patients

Miralles, FP; (...); Casanova, B

Meeting Abstract. 2019


Changes in brain volume in specific regions could predict worsening cognition in primary progressive multiple sclerosis

Perez-Miralles, F; (...); Casanova, B

Meeting Abstract. 2019


Characterization of the gait in patients with relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis measured by FeetMe (R) integrated sensor insole system: Results of the interim analysis

Izquierdo Ayuso, G.; (...); Casanova Estruch, B.

Meeting Abstract. 2021


Chitinase-3-like protein 1 could be a predictor of disability progression in patients with primary progressive multiple sclerosis

Perez-Miralles, F; (...); Casanova, B

Meeting Abstract. 2018


Chitinase-3-like protein 1 could be a predictor of disability progression in patients with primary progressive multiple sclerosis: A one-year follow-up

Perez-Miralles, F; (...); Casanova, B

Meeting Abstract. 2019


Chronic hyperammonemia induces peripheral inflammation that leads to cognitive impairment in rats: reversal by anti-tnfa treatment.

Balzano T; (...); Felipo V

Article. 10.1016/j.jhep.2019.01.008. 2020


Daclizumab in multiple sclerosis.

Perez-Miralles, FC

Review. 10.33588/rn.6608.2018083. 2018


Deciphering Multiple Sclerosis Progression.

Meca-Lallana, Virginia; (...); Perez-Miralles, Francisco Carlos

Review. 10.3389/fneur.2021.608491. 2021


Design and Validation of an Expanded Disability Status Scale Model in Multiple Sclerosis.

Barreiro-Gonzalez, Antonio; (...); Casanova, Bonaventura

Article. 10.1159/000519772. 2022


Different clinical response to interferon beta and glatiramer acetate related to the presence of oligoclonal IgM bands in CSF in multiple sclerosis patients

Casanova, B; (...); Coret, F

Article. 10.1007/s10072-018-3442-y. 2018


DISCOVER STUDY, FIRST ANALYSIS SPECIFIC FOR SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS BURDEN AND COST IN SPAIN: INTERIM ANALYSIS RESULTS

Oreja-Guevara, C; (...); Meca-Lallana, J

Meeting Abstract. 2020


Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology.

Brieva, Luis; (...); Moral, Ester

Article. 10.1016/j.msard.2022.103805. 2022


Disturbed Glucose Metabolism in Rat Neurons Exposed to Cerebrospinal Fluid Obtained from Multiple Sclerosis Subjects

Mathur, D; (...); Burgal-Marti, M

Article. 10.3390/brainsci8010001. 2018


Does benign multiple sclerosis exist?

Verdini Martinez, Laura; (...); Casanova, Bonaventura

Meeting Abstract. 2023


Dynamic 18F-FDG PET to detect differences among patients with progressive and relapsing multiple sclerosis: a pilot study

Quintanilla Bordas, Carlos; (...); Casanova, Bonaventura

Meeting Abstract. 2023


Dyschromatopsia in multiple sclerosis reflects diffuse chronic neurodegeneration beyond anatomical landmarks.

Barreiro-González A; (...); Casanova B

Article. 10.1007/s13760-020-01516-x. 2020


Early Alzheimer's Disease Screening Approach Using Plasma Biomarkers

Alvarez-Sanchez, Lourdes; (...); Chafer-Pericas, Consuelo

Article. 10.3390/ijms241814151. 2023


Early beginning of alemtuzumab: Changing the multiple sclerosis treatment paradigm. Interim analysis of the LEMVIDA study.

Meca-Lallana, J E; (...); Calles Hernandez, C

Article. 10.1016/j.nrleng.2021.06.006. 2023


Early beginning of alemtuzumab: changing the multiple sclerosis treatment paradigm. Interim analysis of the LEMVIDA study

Meca-Lallana, J. E.; (...); Hernandez, C. Calles

Article. 10.1016/j.nrl.2021.06.007. 2024


Early experience with compassionate use of 2 hydroxypropyl-beta-cyclodextrin for Niemann-Pick type C disease: review of initial published cases

Megias-Vericat, JE; (...); Poveda, JL

Review. 10.1007/s10072-017-2833-9. 2017


Economic impact and clinical profile of the secondary progressive multiple sclerosis (SPMS) patient: the DISCOVER study

Oreja-Guevara, C.; (...); Meca-Lallana, J. E.

Meeting Abstract. 2021


Economic impact of the secondary progressive multiple sclerosis in spain: interim analysis of the discover study

Oreja-Guevara, C; (...); Meca-Lallana, J

Meeting Abstract. 2020


Eculizumab for a catastrophic relapse in NMOSD: case report.

Gorriz, David; (...); Casanova, Bonaventura

Article. 10.1007/s10072-023-06971-x. 2023


Effectiveness and Safety of Teriflunomide in Relapsing-Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study.

Meca-Lallana JE; (...); Llarena C

Article. 10.1007/s40120-023-00557-7. 2023


Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study.

Alcala, Carmen; (...); Casanova, Bonaventura

Article. 10.1007/s00415-022-10989-0. 2022


Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study

Alcala, C; (...); Casanova, B

Article. 10.1007/s00415-018-8899-3. 2018


Elevation of Chi3l1 in acute disseminated encephalomyelitis: implications in pathogenesis

Gil-Perotin, S; (...); Casanova-Estruch, B

Meeting Abstract. 2018


Elevation of serum neurofilament light-chain levels disclose possible occult progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient receiving ozanimod: a case report.

Quintanilla-Bordás C; (...); Pérez-Miralles FC

Case Reports. 10.3389/fimmu.2024.1465678. 2024


Escalation vs. Early Intense Therapy in Multiple Sclerosis.

Casanova, Bonaventura, Quintanilla-Bordas, Carlos, Gascon, Francisco

Article. 10.3390/jpm12010119. 2022


Evaluating the complement C1q levels in serum and cerebrospinal fluid in multiple sclerosis patients: Could it serve as a valuable marker in clinical practice?

Tortosa-Carreres J; (...); Pérez-Miralles FC

Article. 10.1016/j.jneuroim.2024.578428. 2024


High Levels of Cerebrospinal Fluid Kappa Free Light Chains Relate to IgM Intrathecal Synthesis and Might Have Prognostic Implications in Relapsing Multiple Sclerosis.

Castillo-Villalba, Jessica; (...); Casanova, Bonaventura

Article. 10.3389/fimmu.2022.827738. 2022


Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial

Zubizarreta, I; (...); Villoslada, P

Article. 10.1073/pnas.1820039116. 2019


Immune tolerance in patients with Multiple Sclerosis and Neuromyelitis Optica by peptide-loaded tolerogenic dendritic cells: final results of the phase 1b clinical trial and extension

Zubizarreta, I; (...); Villoslada, P

Meeting Abstract. 2019


Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart (R) in patients with multiple sclerosis

Edo Solsona MD; (...); Poveda Andrés JL

Article. 10.2147/PPA.S127508. 2017


Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patients' Perspective: An Observational Cross-Sectional Study

Meca-Lallana, Jose E.; (...); Maurino, Jorge

Article. 10.1007/s40120-022-00356-6. 2022


Impact of neuromyelitis optica spectrum disorder on quality of life: Assessing the patients' perspective

Meca-Lallana, Jose; (...); Maurino, Jorge

Meeting Abstract. 10.1016/j.jns.2021.118844. 2021


Impact of stigma in patients with primary progressive multiple sclerosis: a one-year follow-up

Perez-Miralles, F; (...); Casanova, B

Meeting Abstract. 2019


Improvements in Quality of Life of Patients with Multiple Sclerosis receiving Alemtuzumab in Clinical Practice: LEMVIDA study

Meca Lallana, Jose; (...); Forner, Mireia

Meeting Abstract. 10.1212/WNL.0000000000202381. 2023


Improvements in quality of life of patients with multiple sclerosis receiving alemtuzumab in clinical practice: the LEMVIDA study.

Meca-Lallana, Jose Eustasio; (...); Toledo, Baldo

Article. 10.1186/s41687-024-00822-9. 2024


Improving the efficiency of free kappa light chains as diagnostic biomarker of Multiple Sclerosis by using a novel algorithm.

Tortosa-Carreres J; (...); Pérez-Miralles FC

Article. 10.1016/j.msard.2023.104997. 2023


In Situ RT-PCR Optimized For Electron Microscopy Allows Description Of Subcellular Morphology Of Target mRNA-Expressing Cells In the Brain

LAURA CUBAS NÚÑEZ; (...); Gil-Perotin S

Article. 2017

  • Open Access.

In situ RT-PCR Optimized for Electron Microscopy Allows Description of Subcellular Morphology of Target mRNA-Expressing Cells in the Brain

Cubas-Nunez, L; (...); Gil-Perotin, S

Article. 10.3389/fncel.2017.00141. 2017


Increased EBNA1-specific antibody response in primary-progressive multiple sclerosis

Comabella, Manuel; (...); Luenemann, Jan D.

Article. 10.1007/s00415-024-12763-w. 2025


Is it cost-effective to request IgM oligoclonal bands against lipids in daily practice as a biomarker for poor prognosis in multiple sclerosis?

Ribes Garcia, Sara; (...); Bonaventura, Casanova Estruch

Article. 10.1016/j.msard.2023.105033. 2023


Leptomeningeal gadolinium enhancement in multiple sclerosis

Gascon-Gimenez, F; (...); Casanova, V

Meeting Abstract. 2019


Leptomeningeal gadolinium enhancement lesions in multiple sclerosis are not related to different brain volume measures

Garcia, F; (...); Casanova, B

Meeting Abstract. 2018


Long-term efficacy of alemtuzumab in multiple sclerosis: a real word multicenter Spanish experience

Rubio Alcantud, Almudena; (...); Casanova, Bonaventura

Meeting Abstract. 2023


Long-term treatment effect over disability progression in patients with relapsing multiple sclerosis

Estruch, BC; (...); Coret, F

Meeting Abstract. 2017


Magnetic resonance imaging and optical coherence tomography correlations in multiple sclerosis beyond anatomical landmarks.

Barreiro-González A; (...); Casanova B

Article. 10.1016/j.jns.2020.117180. 2020


Milestones of Precision Medicine: An Innovative, Multidisciplinary Overview

Garcia-Foncillas, J; (...); Gomez, MVP

Review. 10.1007/s40291-021-00544-4. 2021


miRNA Signature in CSF From Patients With Primary Progressive Multiple Sclerosis.

Munoz-San Martin, Maria; (...); Ramio-Torrenta, Lluis

Article. 10.1212/NXI.0000000000200069. 2023


Neuromyelitis optica associated with the use of Atezolizumab in a patient with advanced lung adenocarcinoma.

Pedrero Prieto, Manuel; (...); Casanova Estruch, Bonaventura

Article. 10.1007/s10072-023-07252-3. 2023


New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab.

Toboso I; (...); Villar LM

Article. 10.3389/fneur.2020.579438. 2020


NFL during acute spinal cord lesions in MS: a hurdle for the detection of inflammatory activity.

Alcala, C.; (...); Casanova, B.

Article. 10.1007/s00415-021-10926-7. 2022


Oligoclonal M bands and cervical spinal cord lesions predict early secondary progressive multiple sclerosis.

Alcala Vicente, Carmen; (...); Casanova, Bonaventura

Article. 10.3389/fneur.2022.991596. 2022


Oligoclonal M bands distinguish two MS populations based on neurofilament light chain levels in patients without inflammatory activity

Castillo, J.; (...); Casanova, B.

Meeting Abstract. 2022


Oligoclonal M bands unveil occult inflammation in multiple sclerosis.

Casanova B; (...); Pérez-Miralles F

Article. 10.1016/j.msard.2022.104118. 2022


Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies.

Coret F; (...); Casanova B

Article. 10.1177/2055217318783347. 2018


Perception of Stigma in Patients with Neuromyelitis Optica Spectrum Disorder

Meca-Lallana, JE; (...); Maurino, J

Article. 10.2147/PPA.S305707. 2021


Perception of stigma in patients with primary progressive multiple sclerosis.

Pérez-Miralles F; (...); Casanova-Estruch B

Article. 10.1177/2055217319852717. 2019


Perception of stigma in people with neuromyelitis optica spectrum disorders (PERSPECTIVES-NMO Study)

Lallana, Jose Meca; (...); Maurino, Jorge

Meeting Abstract. 2021


Peripapillary retinal nerve fibre layer correlates better with spinal cord volume than with brain parenchymal fraction in multiple sclerosis

Barreiro-Gonzalez, A; (...); Casanova, B

Meeting Abstract. 2019


Potential Biomarkers Associated with Multiple Sclerosis Pathology.

Mathur, Deepali; (...); Casanova, Bonaventura

Article. 10.3390/ijms221910323. 2021


Potential Role of CHI3L1+ Astrocytes in Progression in MS.

Cubas-Núñez L; (...); Casanova B

Article. 10.1212/NXI.0000000000000972. 2021


Predictive potential of serum and cerebrospinal fluid biomarkers for disease activity in treated multiple sclerosis patients.

Tortosa-Carreres J; (...); Pérez-Miralles FC

Article. 10.1016/j.msard.2024.105734. 2024


Predictive value of isolated CSF NfL and Chi3l1 measures in clinical practice

Gil-Perotin, S; (...); Casanova-Estruch, B

Meeting Abstract. 2018


Progressive Demyelination in the Presence of Serum Myelin Oligodendrocyte Glycoprotein-IgG: A Case Report

Gil-Perotin, S; (...); Casanova-Estruch, B

Article. 10.3389/fneur.2018.00340. 2018


Quantifying the patient ' s perspective in neuromyelitis optica spectrum disorder: Psychometric properties of the SymptoMScreen questionnaire

Meca-Lallana, JE; (...); Ballesteros, J

Article. 10.1371/journal.pone.0255317. 2021


Quantifying the patient's perspective in neuromyelitis optica spectrum disorders: design of a multicenter, non-interventional study

Meca-Lallana, J; (...); Maurino, J

Meeting Abstract. 2020


Recommendations for the Diagnosis and Treatment of Multiple Sclerosis Relapses.

Ramo-Tello, Cristina; (...); Rovira À

Article. 10.3390/jpm12010006. 2021


Recurrent and universal alopecia areata following alemtuzumab treatment in multiple sclerosis: A secondary autoimmune disease

Alcala, C; (...); Casanova, B

Editorial Material. 10.1016/j.msard.2018.12.005. 2019


Relationship between different cerebrospinal fluid biomarkers in multiple sclerosis: meaning and use in clinical practice

Castillo, J; (...); Casanova, B

Meeting Abstract. 2017


Renal function influences serum neurofilament light chain levels in patients with multiple sclerosis

Gasque Rubio, R.; (...); Casanova Estruch, B.

Meeting Abstract. 2022


Renal function's impact on serum neurofilament levels in patients with multiple sclerosis: an exploratory analysis.

Tortosa-Carreres, Jordi; (...); Perez-Miralles, Francisco

Article. 10.1007/s10072-024-07772-6. 2024


Review of the novelties from the 32nd ECTRIMS Congress, 2016, presented at the 9th Post-ECTRIMS Meeting (I)

Fernandez, O; (...); Rodriguez-Antiguedad, A

Review. 10.33588/rn.6501.2017168. 2017


Review of the novelties from the 32nd ECTRIMS Congress, 2016, presented at the 9th Post-ECTRIMS Meeting (II)

Fernandez, Oscar; (...); Rodriguez-Antiguedad, Alfredo

Review. 10.33588/rn.6502.2017169. 2017


Revision de las novedades del XXXII Congreso ECTRIMS 2016, presentadas en la IX Reunion Post-ECTRIMS (II).

Fernandez O; (...); Rodriguez-Antiguedad A

Article. 10.33588/rn.6502.2017169. 2017


Risk of transition to secondary progressive multiple sclerosis and accumulation of disability in progressive multiple sclerosis are not influenced by current therapies

Alcala, C; (...); Casanova, B

Meeting Abstract. 2017


SARS-CoV-2 Infection in Multiple Sclerosis: Results of the Spanish Neurology Society Registry.

Arrambide, Georgina; (...); Meca-Lallana, Jose E

Article. 10.1212/NXI.0000000000001024. 2021


Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis.

Fissolo, Nicolas; (...); Comabella, Manuel

Article. 10.1136/jnnp-2023-332251. 2023


Serum biomarkers at disease onset for personalized therapy in multiple sclerosis.

Monreal E; (...); Villar LM

Article. 10.1093/brain/awae260. 2024


Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels at Disease Onset for Prediction of the Risk of Disability Worsening in Patients with Multiple Sclerosis

Monreal, Enric; (...); Villar Guimerans, Luisa Maria

Meeting Abstract. 2023


Serum neurofilament light chain and glial fibrillary acidic protein levels at disease onset unveil immunological pathways of disability acquisition in multiple sclerosis

Monreal, Enric; (...); Villar Guimerans, Luisa Maria

Meeting Abstract. 2024


Serum Neurofilament Light Chain is a surrogate marker of NEDA-3 in Multiple Sclerosis

Gascon Gimenez, Francisco Guillermo; (...); Casanova, Bonaventura

Meeting Abstract. 2023


Short-term data on disease activity, cognition, mood, stigma and employment outcomes in a cohort of patients with primary progressive multiple sclerosis (UPPMS study).

Pérez-Miralles F; (...); Casanova B

Article. 10.1016/j.msard.2021.102860. 2021


Silent Progression or Bout Onset Progressive Multiple Sclerosis?

Gil-Perotin, S; (...); Casanova, B

Letter. 10.1002/ana.25537. 2019


Spanish registry of multiple sclerosis patients on glatiramer acetate 40 mg/ml treatment: Real-world results and baseline characteristics of initial patients

Fernandez, O; (...); Sanchez-de la Rosa, R

Meeting Abstract. 2017


Spinal cord atrophy but not brain atrophy measures, correlates with the Multiple Sclerosis Severity Score

Carratala, S; (...); Estruch, BC

Meeting Abstract. 2018


Sustained hyperammonemia induces TNF-a IN Purkinje neurons by activating the TNFR1-NF-?B pathway.

Balzano T; (...); Felipo V

Article. 10.1186/s12974-020-01746-z. 2020


Symptom severity in Neuromyelitis Optica Spectrum Disorder from the patients' perspective

Meca-Lallana, J.; (...); Maurino, J.

Meeting Abstract. 2021


The impact of stigma in people with primary progressive multiple sclerosis

Perez-Miralles, F; (...); Casanova-Estruch, B

Meeting Abstract. 2018


Treatment of multiple sclerosis with Rituximab: a multicenter Spanish experience

Alcala, C.; (...); Casanova, B.

Meeting Abstract. 2021


Treatment of multiple sclerosis with rituximab: A Spanish multicenter experience.

Gascon-Gimenez, Francisco; (...); Casanova, Bonaventura

Article. 10.3389/fneur.2023.1060696. 2023


Treatment of Multiple Sclerosis With Teriflunomide. Multicenter Study of Real Clinical Practice in the Valencian Community-Spain.

Landete, Lamberto; (...); Casanova, Bonaventura

Article. 10.3389/fneur.2021.727586. 2021


Treatment of relapsing-remitting multiple sclerosis with fingolimod in routine clinical practice

Alcala-Vicente, C; (...); Casanova-Estruch, B

Article. 10.33588/rn.6410.2016359. 2017


Treatment with alemtuzumab after fingolimod in relapsing-remitting multiple sclerosis is effective and safe

Alcala, C; (...); Casanova, B

Meeting Abstract. 2018


Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe

Alcala, C; (...); Casanova, B

Article. 10.1007/s00415-019-09195-2. 2019


Use of 2 hydroxypropyl-beta-cyclodextrin therapy in two adult Niemann Pick Type C patients

García-Robles AA; (...); Poveda JL

Letter. 10.1016/j.jns.2016.04.048. 2016


Campos de estudio

Compartir